Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.
about
Androgen-modulating agents for spinal bulbar muscular atrophy/Kennedy's diseasePathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophyDeveloping treatment for spinal and bulbar muscular atrophyCo-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapyDecreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy.Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMASpinal and bulbar muscular atrophy: pathogenesis and clinical managementIncreased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patientsCorrelation of clinical and molecular features in spinal bulbar muscular atrophy.Muscle matters in Kennedy's disease.Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice.Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophiesHead and Arm Tremor in X-linked Spinal and Bulbar Muscular AtrophySpinal and Bulbar Muscular Atrophy.Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophyEfficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy.Proceedings of the fourth international conference on central hypoventilation.Tremor in X-linked recessive spinal and bulbar muscular atrophy (Kennedy's disease)Mitochondrial dysfunction in Kennedy's disease: a new pharmacological target?Current status of treatment of spinal and bulbar muscular atrophy.Nemo-like kinase is a novel regulator of spinal and bulbar muscular atrophy.Convenient diagnosis of spinal and bulbar muscular atrophy using a microchip electrophoresis system.Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophySpinal and Bulbar Muscular Atrophy Overview.Trinucleotide repeats and protein folding and disease: the perspective from studies with the androgen receptor.Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes.New routes to therapy for spinal and bulbar muscular atrophy.Sirtuin deacetylases in neurodegenerative diseases of aging.SIRT1 in neurodevelopment and brain senescence.Potential therapeutic targets in polyglutamine-mediated diseases.Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future.Targeted Molecular Therapies for SBMA.PolyQ disease: too many Qs, too much function?Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.Swallowing markers in spinal and bulbar muscular atrophy.A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study.Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy.A role for androgen reduction treatment in Kennedy disease?
P2860
Q24187399-F84271F5-0E5D-4B5C-AAC2-F8B1E4757B63Q27007098-664B6380-103A-48A9-A3F9-B669FA88B0F3Q27008808-80BDC7D9-C9C1-4A7D-A45E-432C8FC16A09Q28285156-C0651670-1B41-41BD-8B95-FAD8FC791107Q28555190-C0FCA0DB-8314-4389-B00A-45F9CB6DA362Q30361988-60575458-8328-4CFC-8857-C0FCD16B33F3Q30612908-43AF4684-85FB-4E96-A0B1-BCE2E0F67576Q33614611-F24470A7-E0C3-4841-911D-2B2D4750F957Q33823373-0664DC84-379D-4219-888B-1F46562EEF2DQ33860974-019E6D3A-AA46-4401-8FA3-7380830CD8CAQ34055364-99084040-8EF1-4DD8-A0ED-3AA05E4A1EE9Q34399213-BA8F4486-AC9A-45F8-86BD-D565ADAF09C8Q34446500-58B7A24C-FB29-4D21-AC1C-515C28F74744Q34499899-C0241643-B0FB-487E-8190-CA23ACF47735Q34637225-324A1912-EAFD-4F06-9D66-882C0493619FQ34642189-D78B3493-E00D-4E2C-8373-D054234C74E9Q34666168-99C087BE-C067-48E8-80AE-008CFC1B7993Q34673417-A9ECCC9B-8482-45D6-8913-48E0DE5B8D99Q34721441-75AC3129-0A80-460A-8F0A-ABD39D9F19C7Q35087192-5101CDEA-2497-4E32-8D6D-DDD1CA74038AQ35477408-61CF1760-1829-4CC3-949C-C397F3DC6787Q36037644-304467E3-01A5-42F1-9021-CD3C8195B746Q36081124-B64F4EBA-9672-4A75-803A-A47847D6D019Q36695902-2AF5E103-3DDA-4A0A-9963-4CCE6441D0C8Q36708477-FAA9EDB7-E66B-4503-A077-4C0E7B4565FCQ37392206-AF5382AF-8C24-42EB-A0E2-E2A05BA55FFEQ37474263-BE812CA7-5B13-4F45-BD67-69F35DCBFFBCQ37602169-4E9D258D-DAAA-4056-A197-E5738081881CQ38082664-A87C42CC-C0F2-4400-B6A3-ED9B64E4BBB6Q38108128-5A5485AC-6736-4062-AB03-235050D8577AQ38186171-851558FE-3C03-44F0-8028-30B50F2F2E2EQ38246221-3FE523BB-47AA-434B-AB01-955939C7A31DQ38634370-9074BB1A-CC44-4255-972E-D66C085376EFQ38635851-C07B8906-F1ED-4496-A07A-6241434C1E64Q38791237-83C77D11-2B3E-4B36-817F-877C51E22966Q38792714-49B3185B-DD49-46CB-9A8E-177F406F5780Q41357946-81EB682E-CD42-4238-8EAE-C9B1B279323CQ41708271-6E8670AC-F13D-4612-818A-03FF00232E2DQ42063287-5D98FCA9-0727-4782-8E9F-77A207E71D2CQ42700007-B122DA26-3D40-436A-B7B3-60EDCA818359
P2860
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@ast
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@en
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@nl
type
label
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@ast
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@en
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@nl
prefLabel
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@ast
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@en
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1433
P1476
Efficacy and safety of leupror ...... ind, placebo-controlled trial.
@en
P2093
Akira Tsujino
Fumiaki Tanaka
Fumio Kanda
Haruhiko Banno
Hidehiro Mizusawa
Hidenao Sasaki
Hiroaki Miyajima
Ichiro Yabe
Imaharu Nakano
Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group
P304
P356
10.1016/S1474-4422(10)70182-4
P50
P577
2010-08-04T00:00:00Z